McKesson Corporation (BVMF:M1CK34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 455.04B -10.6% |
| Revenue (ttm) | 2.10T +12.4% |
| Net Income | 24.84B +44.5% |
| EPS | 200.22 +49.2% |
| Shares Out | n/a |
| PE Ratio | 18.32 |
| Forward PE | 17.39 |
| Dividend | 2.69 (0.27%) |
| Ex-Dividend Date | Feb 27, 2026 |
| Volume | 1 |
| Average Volume | 74 |
| Open | 979.00 |
| Previous Close | 969.04 |
| Day's Range | 979.00 - 979.00 |
| 52-Week Range | 891.36 - 1,308.54 |
| Beta | 0.36 |
| RSI | 43.93 |
| Earnings Date | May 7, 2026 |
About McKesson
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services f... [Read more]
Financial Performance
In fiscal year 2026, McKesson's revenue was $403.43 billion, an increase of 12.36% compared to the previous year's $359.05 billion. Earnings were $4.76 billion, an increase of 44.52%.
Financial numbers in USD Financial StatementsNews
McKesson price target lowered to $945 from $975 at Citi
Citi lowered the firm’s price target on McKesson (MCK) to $945 from $975 and keeps a Buy rating on the shares.
McKesson Transcript: Bank of America Global Healthcare Conference 2026
Strong fiscal 2026 results exceeded targets, driven by specialty pharmaceuticals and operational efficiency. Biosimilars and GLP-1s are key growth areas, with automation and AI supporting margin expansion. Strategic M&A and MedSurg separation position the business for continued growth.
McKesson Q4 Earnings Call Highlights
McKesson NYSE: MCK reported a stronger fiscal fourth quarter and full fiscal 2026 performance, with executives pointing to growth across its oncology, multispecialty, pharmaceutical distribution and p...
McKesson price target raised to $1,050 from $1,000 at UBS
UBS analyst Kevin Caliendo raised the firm’s price target on McKesson (MCK) to $1,050 from $1,000 and keeps a Buy rating on the shares. Despite the “messy” Q4 print, the…
McKesson price target lowered to $850 from $950 at Evercore ISI
Evercore ISI lowered the firm’s price target on McKesson (MCK) to $850 from $950 and keeps an Outperform rating on the shares.
McKesson price target lowered to $941 from $1,010 at Baird
Baird analyst Eric Coldwell lowered the firm’s price target on McKesson (MCK) to $941 from $1,010 and keeps an Outperform rating on the shares. The firm updated its model following…
McKesson price target lowered to $875 from $973 at Deutsche Bank
Deutsche Bank analyst George Hill lowered the firm’s price target on McKesson (MCK) to $875 from $973 and keeps a Buy rating on the shares.
McKesson price target lowered to $1,015 from $1,107 at JPMorgan
JPMorgan lowered the firm’s price target on McKesson (MCK) to $1,015 from $1,107 and keeps an Overweight rating on the shares.
McKesson price target lowered to $900 from $1,000 at BofA
BofA analyst Allen Lutz lowered the firm’s price target on McKesson (MCK) to $900 from $1,000 and keeps a Buy rating on the shares. McKesson reported “a mixed quarter,” but…
McKesson expects 2027 profit slightly above estimates on drug distribution strength
McKesson forecast 2027 profit slightly above Wall Street expectations after beating first-quarter profit estimates on Thursday, as the U.S. drug distributor banks on strength in its oncology and spe...
McKesson reports Q4 EPS $11.69, consensus $11.57
Reports Q4 revenue $96.3B, consensus $101.4B.
McKesson sees FY27 EPS $43.80-$44.60, consensus $44.11
Sees Fy27 revenue up 5%-9%, implying $423.6B-$439.7B, consensus $442.44B.
McKesson down 2% at $737 after Q4 results and FY27 guide
16:15 EDT McKesson (MCK) down 2% at $737 after Q4 results and FY27 guide
McKesson Earnings Call Transcript: Q4 2026
Fiscal 2026 saw strong growth with revenues up 12% and adjusted EPS up 18%, driven by specialty and oncology platforms. FY27 guidance projects 12–14% EPS growth, continued capital returns, and progress on the Medical-Surgical Solutions separation.
McKesson Earnings release: Q4 2026
McKesson released its Q4 2026 earnings on May 7, 2026, summarizing the period's financial results.
McKesson Slides: Q4 2026
McKesson has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 7, 2026.
McKesson Annual report: Q4 2026
McKesson has published its Q4 2026 annual report on May 7, 2026.
McKesson Reports Fiscal 2026 Fourth Quarter and Full Year Results, Provides Fiscal 2027 Guidance, and Reaffirms Long-Term Financial Growth Targets
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) has released its fiscal 2026 fourth quarter financial results. Results can be accessed on McKesson's Investor Relations website at inve...
McKesson initiated with an Outperform at William Blair
William Blair initiated coverage of McKesson (MCK) with an Outperform rating. The company has a “durable competitive moat” with specialty-led growth upside, the analyst tells investors in a research n...
McKesson price target lowered to $1,000 from $1,012 at UBS
UBS lowered the firm’s price target on McKesson (MCK) to $1,000 from $1,012 and keeps a Buy rating on the shares.
McKesson Corporation Declares Quarterly Dividend
IRVING, Texas--(BUSINESS WIRE)--The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 82 cents per share of common stock. The dividend will be payable on J...
Is McKesson Stock Still A High-Conviction Compounder?
McKesson's net earnings increased at an average rate of 14.4% over the previous three years, while its earnings per share (EPS) grew by 19.6% annually in that same period. This 5.2% disparity indicate...
McKesson to Sell Stake of Medical-Surgical Unit to Apollo
McKesson said Apollo affiliates agreed to buy a minority ownership interest in its medical-surgical solutions business ahead of the unit's planned spinoff.
McKesson sells minority stake in surgical supplies unit to Apollo Funds for $1.25 billion
McKesson said on Monday it will sell a minority stake in its medical-surgical solutions business to investment firm Apollo Funds for $1.25 billion, as it prepares to spin off the unit through an i...